Tariffs on Canadian imports and higher taxes on generic drugs are shaking up expectations for costs and pricing across healthcare. For U.S. specialty pharmaceutical manufacturers, this mix of pressure and opportunity can be important. Some companies may face higher input costs. Others with more domestic production may see a relative edge if imported generics become more expensive. This article explains how the new trade measures could matter for your portfolio and discusses 3 U.S. specialty pharma stocks that appear particularly exposed to this news, all on the positive side, based on their business profiles and current trade headlines.

ANI Pharmaceuticals (ANIP)

Overview: ANI Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets a mix of generic and branded treatments, including injectables, softgel capsules, Cortrophin Gel and eye implants such as ILUVIEN and YUTIQ, which it supplies to wholesalers, pharmacies, hospitals and healthcare providers in the U.S. and abroad.

Operations: ANI Pharmaceuticals generates US$405.6m from Generics and Other products and US$518.1m from its Rare Disease and Brands segment.

Market Cap: US$1.71b

ANI Pharmaceuticals stands out in the current tariff-heavy backdrop because more than 90% of its revenue comes from finished drugs made in the U.S., which could give it a pricing and supply advantage if imported generics face higher costs. At the same time, the company is focusing on higher margin rare disease treatments such as Cortrophin Gel and eye implants, supported by recent positive trial data, to affect earnings quality. Investors may want to monitor its debt load, product recalls and ongoing insider selling, which all add financial and execution risk. The combination of domestic manufacturing, a rare disease portfolio and active capital return through buybacks makes ANI Pharmaceuticals a stock many investors are watching closely right now.

ANI Pharmaceuticals looks like a company whose U.S. manufacturing and rare disease focus could be masking an even bigger story for margins and resilience. Before you decide what that might mean for your portfolio, review the 4 key rewards and 3 important warning signs

Viatris (VTRS)

Overview: Viatris is a global healthcare company that supplies a wide range of branded drugs, generics, complex generics and biosimilars across major therapeutic areas, from cardiovascular and diabetes to oncology and respiratory care. Its products, which include well known brands like Lyrica, Lipitor, EpiPen Auto-Injector and Viagra, reach patients in more than 160 countries through pharmacies, hospitals, payers and government channels.

Operations: Viatris generates US$8.68b from Developed Markets, US$2.46b from Greater China, US$2.23b from Emerging Markets and US$1.19b from its JANZ segment.

Market Cap: US$20.68b

Viatris sits at the center of the tariff story because it already produces more than half of its U.S. revenue domestically and runs eight manufacturing and R&D sites in the country. This footprint could give it pricing power if imported generics become more expensive under the new trade rules. At the same time, the company is still working through reliance on mature, lower margin generics, debt funded capital returns and regulatory pressure. New products such as the once weekly Gwyn Lo contraceptive patch and late stage assets such as fast acting meloxicam and VR 205 signal a shift toward higher value therapies. For investors, the combination of a low P/S rating, changes in profitability and direct exposure to tariff related generic pricing may be important factors to consider beyond the headlines.

Viatris appears to be a company where mature generics and new therapies are pulling in different directions, and that gap could be important for valuation. Get the fuller picture in the analysis report for Viatris

Supernus Pharmaceuticals (SUPN)

Overview: Supernus Pharmaceuticals focuses on treatments for central nervous system conditions in the U.S., selling a portfolio of prescription drugs for ADHD, epilepsy, Parkinson’s disease and related movement disorders through wholesalers, specialty pharmacies and distributors.

Operations: Supernus Pharmaceuticals generates US$776.8m in revenue from its Pharmaceuticals segment, all from the United States.

Market Cap: US$2.65b

Supernus Pharmaceuticals is attracting attention because it combines a focused U.S. CNS portfolio with potential tariff insulation on key products like Qelbree, Trokendi XR, GOCOVRI, ONAPGO and APOKYN, which management indicates are either made domestically or covered by arrangements that reduce exposure to import taxes. At the same time, the company still depends heavily on a handful of drugs, faces higher gross to net pressure on pricing and continues to invest heavily in R&D and launches, which has kept it unprofitable despite higher revenue. For investors watching U.S. specialty pharma, the mix of revenue expectations, a deep pipeline and a P/S multiple that sits well below peers raises the question of whether the current price fully reflects both the tariff benefit and the execution risks.

Supernus Pharmaceuticals looks like a story where a focused CNS portfolio and tariff insulation could be masking how much room the business model still has to evolve. To see how revenue expectations stack up against that potential, review the analyst forecasts for Supernus Pharmaceuticals

The three U.S. specialty pharmaceutical manufacturers in this article are only a starting point, since the full U.S. Specialty Pharmaceutical Manufacturers screener surfaces 7 more companies with equally compelling tariff and business model stories. Use Simply Wall St to identify the specific catalysts, balance sheet strength and valuation narratives that matter most to you so you can analyze the highest conviction ideas in this space.

Take Control of Your Investment Journey

If Viatris or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Beyond These Stocks?

Fresh ideas can move quickly once momentum builds and the best entry points rarely stay open for long. Scan these under the radar opportunities before the crowd and get in early.

• Spot companies where strong balance sheets back the story and use the list of solid balance sheet and fundamentals (45 results) to see which stocks still look compelling while it matters most.
• Track where dependable income meets resilience by running the 9 dividend fortresses and compare yields before prices catch up to the payouts investors are locking in today.
• Find under the radar growth stories that could catch a strong wave of momentum using the 81 resilient stocks with low risk scores so you do not miss the next breakout phase.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.